Compare AG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | PRAX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.0B |
| IPO Year | 2004 | 2020 |
| Metric | AG | PRAX |
|---|---|---|
| Price | $17.25 | $256.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $21.92 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 12.0M | 430.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.41 | N/A |
| Revenue Next Year | $10.68 | $7,758.26 |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.74 | $37.25 |
| 52 Week High | $32.00 | $366.52 |
| Indicator | AG | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 31.62 |
| Support Level | $15.54 | $157.29 |
| Resistance Level | $17.37 | $342.62 |
| Average True Range (ATR) | 1.04 | 21.07 |
| MACD | -0.32 | -10.83 |
| Stochastic Oscillator | 9.23 | 6.31 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.